Oligonucleotide-Based Therapies for Renal Diseases
Fernando Cartón-García1,2, Cassondra Jeanette Saande2, Daniel Meraviglia-Crivelli1
1Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of Navarra, 31008 Pamplona, Spain.
Biomedicines
|April 3, 2021
Summary
New oligonucleotide therapies show promise for chronic kidney disease (CKD). Research focuses on improving kidney delivery and reducing side effects for these advanced treatments.
Area of Science:
- Nephrology
- Biotechnology
- Pharmacology
Background:
- Chronic kidney disease (CKD) presents a growing global health challenge with significant healthcare costs.
- Progressive nature of CKD necessitates the development of novel therapeutic strategies.
- Oligonucleotide-based drugs offer a promising alternative to conventional treatments for CKD.
Purpose of the Study:
- To review preclinical oligotherapeutic strategies for CKD.
- To highlight recent advancements in CKD molecular understanding and drug development.
- To discuss challenges and solutions for efficient kidney drug delivery.
Main Methods:
- Review of preclinical studies on oligotherapeutic agents for CKD.
- Analysis of strategies for enhancing kidney-specific drug delivery.
- Evaluation of nanotechnological platforms for oligonucleotide delivery.
Main Results:
- Oligonucleotide drugs show encouraging preclinical results for CKD.
- Two oligonucleotide candidates are currently in clinical trials.
- Nanotechnology platforms demonstrate potential for targeted kidney delivery.
Conclusions:
- Oligonucleotide-based therapies represent a promising frontier for CKD treatment.
- Efficient kidney delivery and mitigation of off-target effects are critical for clinical translation.
- Nanocarriers, nanoparticles, viral vectors, and aptamers offer potential solutions for targeted delivery.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
179
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
179
01:28Renal Drug Excretion: Tubular Secretion
507
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
507
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
653
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
653
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
127
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
127
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:11Renal Failure: Dose Adjustments
232
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
232